New cell therapy targets Hard-to-Treat cancers in early trial
NCT ID NCT06821048
First seen Jan 31, 2026 · Last updated Apr 30, 2026 · Updated 13 times
Summary
This early-phase study tests a new cell therapy called PTC13 (a type of CAR-T) for people with advanced solid tumors that have not responded to standard treatments. The therapy targets a protein called CEA found on many cancer cells, including colorectal, stomach, and pancreatic cancers. The main goals are to check safety and find the best dose. About 18 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU)
RECRUITINGHangzhou, Zhejiang, 310006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.